Key result
Treatment with both anthracycline and a heart radiation dose ≥30Gy multiplied the risk of cardiac disease by 61.5 (95% CI 19.6-192.8) compared to no anthracycline and radiation <0.1Gy.
Why the study?
Does treatment with anthracyclines and/or radiotherapy increase the risk of cardiac disease in 5-year survivors of childhood cancer?
Population
3,162 5-year survivors of childhood cancer
Comparison
Childhood cancer therapy including anthracycline… vs Patients who received no anthracycline and…
Design
Cohort
Follow-up
up to 40 years of age
Authors
Loading...
CD risk may relate to childhood HRD; leaves open optimal thresholds and needs prospective validation.
Cohort (n=3,162)
Does treatment with anthracyclines and/or radiotherapy increase the risk of cardiac disease in 5-year survivors of childhood cancer?
Relative Risk: 61.5 (95% CI 19.6–192.8)
Childhood cancer survivors treated with anthracyclines and/or high-dose chest radiation face a massively elevated, dose-dependent risk of developing cardiac disease by age 40.
Haddy et al. (2015) conducted a cohort in Childhood cancer survivors (n=3,162). Heart radiation dose and anthracycline vs. No anthracycline and either no radiotherapy or heart radiation dose <0.1Gy was evaluated on Cardiac disease (RR 61.5, 95% CI 19.6-192.8). Treatment with both anthracycline and a heart radiation dose ≥30Gy multiplied the risk of cardiac disease by 61.5 (95% CI 19.6-192.8) compared to no anthracycline and radiation <0.1Gy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: